Johnson & Johnson MedTech Highlights Newest Impella Heart Pump and Long-Term Survival Data at TCT 2025

Danvers, MA – Oct 24, 2025 – Johnson & Johnson MedTech, a global leader in heart recovery, will feature the latest long-term data confirming the survival benefit of Impella CP and present the newest Impella innovations during the upcoming Transcatheter Cardiovascular Therapeutics (TCT) conference October 25 – 28 in San Francisco.

There is robust evidence showing the survival benefit of Impella CP, including the DanGer Shock randomized controlled trial (RCT) published in The New England Journal of Medicineⁱ. This evidence has led to upgraded recommendations for Impella in recent multi-society guidelines, including ACC/AHA, for the treatment of cardiogenic shock patients.

“Over the last two decades, we have defined and advanced the science of unloading,” said Navin Kapur, MD, chief medical and scientific officer for heart recovery, Johnson & Johnson MedTech. “We are committed to leading in innovation – as demonstrated through nine generations of Impella CP – and tackling some of the greatest challenges in the cardiovascular space because we want to help as many patients as possible have an opportunity for heart recovery.”

Nine Generations of Impella CP Innovation

Built on a legacy of delivering for patients, the ninth generation Impella CP represents a decade of innovation in action. The newest design updates optimize functionality and enhance ease of use. Attendees will have the opportunity to see these innovations firsthand at TCT in the Johnson & Johnson MedTech booth #1348.

Highlighting Guideline Updates

Over the past 18 months, Impella microaxial intravascular flow pumps have been highlighted and upgraded in global guidelines for both cardiology and surgery:

• The American College of Cardiology/American Heart Association (ACC/AHA) guidelines for acute coronary syndrome (ACS) upgraded the Impella CP microaxial intravascular flow pump to a Class 2a due to data showing increase survival in patients with ST-segment elevation myocardial infarction (NSTEMI) and cardiogenic shock.ⁱⁱ

• The American Academy of Thoracic Surgery (AATS) Expert consensus statement elevated Impella recommendations in patients with acute myocardial infarction cardiogenic shock (AMICS) to Class 1.ⁱⁱⁱ

• The European Association for Cardio-Thoracic Surgeons, the American Association for Thoracic Surgery and the Society for Thoracic Surgery released the first joint guidelines on temporary mechanical circulatory support (inclusive of Impella) in cardiac surgery, recommending it as a Class 1 intervention for adult patients with cardiogenic shock.^iv

Durability of Survival Benefits Confirmed from the DanGer Shock RCT

Recent data from the DanGer Shock Randomized Controlled Trial, published in the New England Journal of Medicine^v, confirms the long-term survival benefit of Impella:

• At up to 10 years, patients treated with Impella CP experienced an absolute mortality reduction of 16.3% compared to standard care.^vi

• On average, compared to standard care, Impella CP patients gained approximately 600 additional days alive at 10 years.^vii

New DanGer Shock Data to be Presented at TCT

Insights from new sub analyses of the DanGer Shock RCT will be presented. Data on Impella support for HR-PCI patients as well as live and recorded cases with physicians utilizing Impella will be featured during TCT. See the table below for information and click here for the TCT program online. 

Heart Recovery is also hosting a lunch symposium, “Elevating your Clinical Practice for the New Era of Treating Cardiogenic Shock Patients,” on Monday, October 27, during the TCT World Connect Symposium (12:15 PM — 1:30 PM PDT, Presentation Theater 4, Hall E). Brian Kolski, MD,^viii will share the latest from the OASIS study; Daniel Burkhoff, MD,^ix, will speak about long-term DanGer RCT data; and Ramesh Mazhari, MD,^x will highlight shock escalation optimization. The symposium will be available via livestream for TCT registrants.

About Impella 

Impella, the world’s smallest heart pump, is inserted into the heart to temporarily take over the heart’s pumping function, allowing the heart to rest and recover while maintaining the flow of oxygenated blood throughout the body. This therapy allows patients to return to their life and families with their native heart and experience an equal – or improved – quality of life. 

About Cardiovascular Solutions from Johnson & Johnson MedTech  
Across Johnson & Johnson, we are tackling the world’s most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation we are addressing conditions with significant unmet needs such as heart failure, coronary artery disease, stroke, and atrial fibrillation. We are the global leaders in heart recovery, circulatory restoration and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care, committed to taking on two of the leading causes of death worldwide in heart failure and stroke. For more, visit www.heartrecovery.com and follow us on LinkedIn and @jjmt_heartrecov. 

About Johnson & Johnson 
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in cardiovascular, orthopedics, surgery and vision solutions at https://thenext.jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn.  

Cautions Concerning Forward-Looking Statements 

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995 related to the Impella Platform. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: competition, including technological advances, new products and patents attained by competitors; uncertainty of commercial success for new products; the ability of the company to successfully execute strategic plans; impact of business combinations and divestitures; challenges to patents; changes in behavior and spending patterns or financial distress of purchasers of health care products and services; and global health care reforms and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.  

© Johnson & Johnson and its affiliates 2025. All rights reserved. US_ELP_ULTR_399314

Media Contacts:

Erin Farley 

[email protected] 

Jenny Leary 

[email protected]